Shedding Light on the Cellular Uptake Mechanisms of Bioactive Glass Nanoparticles as Controlled Intracellular Delivery Platforms: A Review of the Recent Literature
Damian-Buda AI., Boccaccini AR.
Narrative Review, published in Adv Healthc Mater (2026) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Narrative Review
- Journal
- Adv Healthc Mater (2026)
- Reported sample size
- —
- Source database
- Europe PMC
- PMID
- 40963485
- PMCID
- PMC12790330
- DOI
- 10.1002/adhm.202502754
- Citations
- 5
Abstract (original English)
Recent advancements in nanotechnology have enabled the synthesis of bioactive glass nanoparticles (BGNs), promising multifunctional platforms for the simultaneous delivery of therapeutic ions and biomolecules. However, the intracellular efficiency of BGNs is limited by the internalization mechanism, further dictating the intracellular trafficking and fate. Following a general overview of the main uptake pathways of nanoparticles and the subsequent intracellular localization, a comprehensive analysis of the BGNs' internalization process is presented. Key findings reveal that the BGNs are mainly internalized by active transport mechanisms and are entrapped in endosomes/lysosomes, limiting their ability to exert their full intracellular therapeutic potential. Existing studies in the literature provide valuable data to correlate the uptake process with the intracellular BGN localization, but there is limited research on the fate of BGNs and the released ions once entrapped in intracellular vesicles. Therefore, in the last part, future strategies to either escape the endosome or use the lysosomal degradation as a mechanism for controlled intracellular ion release with implications for targeted modulation of cell behavior are discussed. Going beyond BGNs, this review highlights the need of understanding better the dynamically transforming degradable nanoparticles - an essential step
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.